Goserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover

File(s)

Goserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover.pdf (1.54 MB)

Published version

Show more

Author(s)

Wilson, C

Gossiel, F

Leonard, R

Anderson, RA

Adamson, DJ

more

Type

Journal Article

Date Issued

2016-02-11

Date Acceptance

2016-02-06

Citation

Journal of Bone Oncology, 2016, 5 (1), pp.43-49

URI

http://hdl.handle.net/10044/1/31560

DOI

https://www.dx.doi.org/10.1016/j.jbo.2016.02.003

ISSN

2212-1366

Publisher

Elsevier

Start Page

43

End Page

49

Journal / Book Title

Journal of Bone Oncology

Volume

5

Issue

1

Copyright Statement

© 2016 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

License URL

http://creativecommons.org/licenses/by-nc-nd/4.0/

Identifier

PII: S2212-1374(15)30074-9

Subjects

Bone turnover markers

Breast cancer

Chemotherapy

Goserelin

Primary ovarian insufficiency

Publication Status

Published